During the last session, Organogenesis Holdings Inc (NASDAQ:ORGO)’s traded shares were 1.25 million, with the beta value of the company hitting 1.69. At the end of the trading day, the stock’s price was $5.64, reflecting an intraday loss of -6.24% or -$0.37. The 52-week high for the ORGO share is $6.71, that puts it down -18.97 from that peak though still a striking 61.7% gain since the share price plummeted to a 52-week low of $2.16. The company’s market capitalization is $714.68M, and the average trade volume was 1.65 million shares over the past three months.
Organogenesis Holdings Inc (ORGO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. ORGO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.03.
Organogenesis Holdings Inc (NASDAQ:ORGO) trade information
Organogenesis Holdings Inc (ORGO) registered a -6.24% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -6.24% in intraday trading to $5.64, hitting a weekly high. The stock’s 5-day price performance is 83.55%, and it has moved by 61.93% in 30 days. Based on these gigs, the overall price performance for the year is 95.66%.
The consensus price target of analysts on Wall Street is $5, which implies a decrease of -12.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, ORGO is trading at a premium of 11.35% off the target high and 11.35% off the low.
Organogenesis Holdings Inc (ORGO) estimates and forecasts
In the rating firms’ projections, revenue will increase 1.29% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 90.77M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 102.17M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 109.98M and 130.23M respectively. In this case, analysts expect current quarter sales to shrink by -17.47% and then drop by -21.55% in the coming quarter.
While earnings are projected to return 475.00% in 2025.
ORGO Dividends
Organogenesis Holdings Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 11.52 million shares, is of SOLEUS CAPITAL MANAGEMENT, L.P.’s that is approximately 8.6888% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $32.25 million.
Also, the Mutual Funds coming in first place with the largest holdings of Organogenesis Holdings Inc (ORGO) shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund . Data provided on Dec 31, 2024 indicates that iShares Russell 2000 ETF owns about 1.95 shares. This amounts to just over 1.54 percent of the company’s overall shares, with a $11.0 million market value. The same data shows that the other fund manager holds slightly less at 1.59, or about 1.25% of the stock, which is worth about $8.95 million.
